145 related articles for article (PubMed ID: 35123516)
1. Adaptive dose escalated radiotherapy in oropharyngeal cancers: a treatment planning feasibility study.
Grocutt L; Paterson C; Valentine RM
Radiat Oncol; 2022 Feb; 17(1):24. PubMed ID: 35123516
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
3. Predicting personalised and progressive adaptive dose escalation to gross tumour volume using knowledge-based planning models for inoperable advanced-stage non-small cell lung cancer patients treated with volumetric modulated arc therapy.
Tambe NS; Pires IM; Moore C; Wieczorek A; Upadhyay S; Beavis AW
Biomed Phys Eng Express; 2022 Mar; 8(3):. PubMed ID: 35189613
[No Abstract] [Full Text] [Related]
4. Potential of intensity-modulated radiotherapy to escalate doses to head-and-neck cancers: what is the maximal dose?
Zhou J; Fei D; Wu Q
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):673-82. PubMed ID: 14529771
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Multi-Criteria Optimization-based Trade-Off exploration in combination with RapidPlan for head & neck radiotherapy planning.
Miguel-Chumacero E; Currie G; Johnston A; Currie S
Radiat Oncol; 2018 Nov; 13(1):229. PubMed ID: 30470254
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of PET-CT based hypofractionated accelerated dose escalation in oropharyngeal cancers: Final dosimetric results of the VORTIGERN study. (Secondary endpoint of UK NCRI portfolio: MREC No: 08/H0907/127, UKCRN ID 7341).
Chatterjee S; Kelly C; Arunsingh M; Chakrabarty C; Mott J
J Cancer Res Ther; 2015; 11(2):391-6. PubMed ID: 26148606
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous modulated accelerated radiation therapy for esophageal cancer: a feasibility study.
Zhang WZ; Chen JZ; Li DR; Chen ZJ; Guo H; Zhuang TT; Li DS; Zhou MZ; Chen CZ
World J Gastroenterol; 2014 Oct; 20(38):13973-80. PubMed ID: 25320535
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation in oropharyngeal cancer: a comparison of simultaneous integrated boost and brachytherapy boost.
Embring A; Onjukka E; Mercke C; Lax I; Berglund A; Friesland S
Radiat Oncol; 2023 Apr; 18(1):65. PubMed ID: 37029424
[TBL] [Abstract][Full Text] [Related]
9. Short-course PET based simultaneous integrated boost for locally advanced cervical cancer.
Arnesen MR; Rekstad BL; Stokke C; Bruheim K; Løndalen AM; Hellebust TP; Malinen E
Radiat Oncol; 2016 Mar; 11():39. PubMed ID: 26968827
[TBL] [Abstract][Full Text] [Related]
10. Escalation of radiotherapy dose in large locally advanced drug-resistant gastrointestinal stromal tumors by multi-shell simultaneous integrated boost intensity-modulated technique: a feasibility study.
Cui H; Li Y; Huang W; Lu W; Yi X
Radiat Oncol; 2022 Dec; 17(1):216. PubMed ID: 36578008
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. I: dosimetric results.
Wu Q; Mohan R; Morris M; Lauve A; Schmidt-Ullrich R
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):573-85. PubMed ID: 12738335
[TBL] [Abstract][Full Text] [Related]
12. Focal boost to residual gross tumor volume in brachytherapy for cervical cancer-A feasibility study.
Thiruthaneeswaran N; Groom N; Lowe G; Bryant L; Hoskin PJ
Brachytherapy; 2018; 17(1):181-186. PubMed ID: 29153466
[TBL] [Abstract][Full Text] [Related]
13.
Qiu J; Lv B; Fu M; Wang X; Zheng X; Zhuo W
Head Neck; 2017 Dec; 39(12):2519-2527. PubMed ID: 28963789
[TBL] [Abstract][Full Text] [Related]
14. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach.
Leclerc M; Maingon P; Hamoir M; Dalban C; Calais G; Nuyts S; Serre A; Grégoire V
Radiother Oncol; 2013 Mar; 106(3):333-40. PubMed ID: 23541643
[TBL] [Abstract][Full Text] [Related]
15. Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy.
Lee E; Zeng J; Miyaoka RS; Saini J; Kinahan PE; Sandison GA; Wong T; Vesselle HJ; Rengan R; Bowen SR
Med Phys; 2017 Jul; 44(7):3418-3429. PubMed ID: 28453861
[TBL] [Abstract][Full Text] [Related]
16. Adaptive radiotherapy for locally advanced non-small-cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control.
Guckenberger M; Richter A; Wilbert J; Flentje M; Partridge M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e275-82. PubMed ID: 21497450
[TBL] [Abstract][Full Text] [Related]
17. Defining the dose-volume criteria for laryngeal sparing in locally advanced oropharyngeal cancer utilizing split-field IMRT, whole-field IMRT and VMAT.
Wilke C; Takiar V; Wang H; Moreno AC; Tung SS; Quinlan-Davidson SR; Garden AS; Rosenthal DI; Fuller CD; Gunn GB; Reddy JP; Morrison WH; Wang C; Zhao G; Hutcheson KA; Phan J
J Appl Clin Med Phys; 2021 Jan; 22(1):37-44. PubMed ID: 33277960
[TBL] [Abstract][Full Text] [Related]
18. Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : Planning study in esophageal carcinoma.
Fakhrian K; Oechsner M; Kampfer S; Schuster T; Molls M; Geinitz H
Strahlenther Onkol; 2013 Apr; 189(4):293-300. PubMed ID: 23443611
[TBL] [Abstract][Full Text] [Related]
19. Treatment planning strategy for whole-brain radiotherapy with hippocampal sparing and simultaneous integrated boost for multiple brain metastases using intensity-modulated arc therapy.
Pokhrel D; Sood S; McClinton C; Shen X; Lominska C; Saleh H; Badkul R; Jiang H; Mitchell M; Wang F
Med Dosim; 2016 Winter; 41(4):315-322. PubMed ID: 27692518
[TBL] [Abstract][Full Text] [Related]
20. Non-coplanar beam intensity modulation allows large dose escalation in stage III lung cancer.
Derycke S; Van Duyse B; De Gersem W; De Wagter C; De Neve W
Radiother Oncol; 1997 Dec; 45(3):253-61. PubMed ID: 9426119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
